Journal of Endocrinological Investigation

, Volume 21, Issue 10, pp 707–720 | Cite as

Non-classic adrenal hyperplasia in hyperandrogenism: A reappraisal

  • C. Morán
  • E. S. Knochenhauer
  • Ricardo Azziz
Review Article
First Online:

Key-words

Adrenal adrenal hyperplasia androgens androgen excess polycystic ovary syndrome 21-hydroxylase 3β-hydroxysteroid dehydrogenase 11β-hydroxylase 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Speiser P.W., Dupont B., Rubinstein P., Piazza A., Kastelan A., New M.I. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am. J. Hum. Genet. 37: 650, 1985.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Cobin R.H., Futterweit W., Fiedler R.P., Thornton J.C. Adrenocorticotropic hormone testing in idiopathic hirsutism and polycystic ovarian disease: a test of limited usefulness. Fertil. Steril. 44: 224, 1985.PubMedGoogle Scholar
  3. 3.
    Pang S., Lerner A.J., Stoner E., Levine L.S., Oberfield S.E., Engel I., New M.I. Late-onset adrenal steroid 3β-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women. J. Clin. Endocrinol. Metab. 60: 428, 1985.PubMedCrossRefGoogle Scholar
  4. 4.
    Azziz R., Zacur H.A. 21-Hydroxylase Deficiency in female hyperandrogenism: Screening and Diagnosis. J. Clin. Endocrinol. Metab. 69: 577, 1989.PubMedCrossRefGoogle Scholar
  5. 5.
    Azziz R., Bradley Jr. E.L., Potter H.D., Boots L.R. 3β-hydroxysteroid dehydrogenase deficiency in hyperandrogenism. Am. J. Obstet. Gynecol. 168: 889, 1993.PubMedCrossRefGoogle Scholar
  6. 6.
    Chetkowski R.J., DeFazio J., Shamonki I., Judd H.L., Chang R.J. The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women. J. Clin. Endocrinol. Metab. 58: 595, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Innanen V.T., Vale J.M. Assessment of the one hour adrenocorticotrophic hormone test in the diagnosis of attenuated 21-hydroxylase deficiency. J. Clin. Pathol. 43: 493, 1990.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    McLaughlin B., Barrett P., Finch T., Devlin JG. Late onset adrenal hyperplasia in a group of Irish females who presented with hirsutism, irregular menses and/or cystic acne. Clin. Endocrinol. 32: 57, 1990.CrossRefGoogle Scholar
  9. 9.
    Kutteenn F., Couillin P., Girard F., Billaud L., Vincens M., Boucekkine C., Thalabard J. C., Maudelonde T., Spritzer P., Mowszowics I., Boue A., Mauvais-Jarvis P. Late-onset adrenal hyperplasia in hirsutism. N. Engl. J. Med. 313: 224, 1985.CrossRefGoogle Scholar
  10. 10.
    Carmina E., Malizia G., Janni A. Prevalence of late-onset 21-hydroxylase deficiency in hirsutism of western sicily. J. Endocrinol. Invest. 10: 75, 1987.Google Scholar
  11. 11.
    Motta P., Catania A., Airaghil, Mangone I., Cantalamessa L., Zanussi C. Prevalence of late-onset adrenal hyperplasia in postmenarchal hirsutism. J. Endocrinol. Invest. 11: 675, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Mithal A., Ammini A.C., Godbole M.M., Khurana M.L., Raj D., Karmarkar M.G., Ahuja M.M.S. Late-onset adrenal hyperplasia in North Indian hirsute women. Horm. Res. 30: 1, 1988.PubMedCrossRefGoogle Scholar
  13. 13.
    Khandekar S., Lata V., Dash R.J. Screening for late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Indian J. Med. Res. 92: 79, 1990.PubMedGoogle Scholar
  14. 14.
    Arnaout M.A. Late-onset congenital adrenal hyperplasia in women with hirsutism. Eur. J. Clin. Invest. 22: 651, 1992.PubMedCrossRefGoogle Scholar
  15. 15.
    Eldar-Geva T., Hurwitz A., Vecsei P., Palti Z., Milwidsky A., Rosier A. Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. N. Engl. J. Med. 323: 855, 1990.PubMedCrossRefGoogle Scholar
  16. 16.
    Speiser P.W., Serrat J., New M.I., Gertner J.M. Insulin insensitivity in adrenal hyperplasia due to non-classical steroid 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 75: 1421, 1992.PubMedGoogle Scholar
  17. 17.
    Levin J.H., Carmina E., Lobo R.A. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Fertil. Steril. 56: 635, 1991.PubMedGoogle Scholar
  18. 18.
    Azziz R., Dewailly D., Owerbach D. Non-classic adrenal hyperplasia: Current concepts. J. Clin. Endocrinol. Metab. 78: 810, 1994.PubMedGoogle Scholar
  19. 19.
    Dewailly D., Vantyghem-Haudiquet MC., Sainsard C., Buvat J., Cappoen JP., Ardaens K., Racadot A., Lefebvre J., Fossati P. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 63: 418, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Levine L.S., Dupont B., Lorenzen F., Pang S., Pollack M., Oberfield S.E., Kohn B., Lerner A., Cacciari E., Mantero F., Cassio A., Scaroni C., Chiumello G., Rondanini G.F., Gargantini L., Migliori C., Pintor C., Tato L., Barboni F., New M.I. Cryptic 21-hydroxylase deficiency in families of patients with classical congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 51: 1316, 1980.PubMedCrossRefGoogle Scholar
  21. 21.
    Auchterlonie I.A., Cameron J., Wallace A.M., Rudd B.T., Hudson M., Smail P.J. Pre-pubertal gynaecomastia as the presenting feature of lateonset 21-hydroxylase deficiency. Horm. Res. 22: 94, 1985.PubMedCrossRefGoogle Scholar
  22. 22.
    New M.I., Gertner J.M., Speiser P.W., Del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J. Endocrinol. Invest. 12: 91, 1989.PubMedGoogle Scholar
  23. 23.
    Augarten A., Weissenberg R., Pariente C., Sack J. Reversible male infertility in late onset congenital hyperplasia. J. Endocrinol. Invest. 14: 237, 1991.PubMedCrossRefGoogle Scholar
  24. 24.
    Miller W.L. Molecular biology of steroid hormone synthesis. Endocr. Rev. 9: 295, 1988.PubMedCrossRefGoogle Scholar
  25. 25.
    Miller W.L. Genetics, diagnosis, and management of 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 78: 241, 1994.PubMedGoogle Scholar
  26. 26.
    Knochenhauer E.S., Decanter C., Cortet-Rudelli C., Morel Y., Conway-Myers B.A., Dewailly D., Azziz R. Genotype in women with 21-hydroxylase (21-OH) deficient nonclassic adrenal hyperplasia (NCAH). Endocrine Society, P1–369, 1996 (Abstract).Google Scholar
  27. 27.
    Witchel S.F., Bhamidipati D.K., Hoffman E.P., Cohen J.B. Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 81: 4081, 1996.PubMedGoogle Scholar
  28. 28.
    Wassarman D.A., Steitz J.A. Interactions of small nuclear RNA’s with precursor messenger RNA during in vitro splicing. Science 257: 1918, 1992.PubMedCrossRefGoogle Scholar
  29. 29.
    Carrera P., Bordone L., Azzani T., Brunelli V., Garancini M.P., Chiumello G., Ferrari M. Point mutations in Italian patients with classic, non-classic, and cryptic forms of steroid 21-hydroxylase deficiency. Hum. Genet. 98: 662, 1996.PubMedCrossRefGoogle Scholar
  30. 30.
    Helmberg A., Tusie-Luna M.T., Tabarelli M., Kofler R., White P.C. R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficience that are not apparent gene conversions. Mol. Endocrinol. 6: 1318, 1992.PubMedGoogle Scholar
  31. 31.
    Morel Y., Miller W.L. Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv. Hum. Genet. 20: 1, 1991.PubMedGoogle Scholar
  32. 32.
    Chiou S.H., Hu M.C., Chung B. A missense mutation of Ile 172 to Asn or Arg 356 to Trp causes steriod 21-hydroxylase deficiency. J. Biol. Chem. 256: 3549, 1990.Google Scholar
  33. 33.
    Higashi Y., Hiromasa T., Tanae A., et al. Effects of individual mutations in the P-450c21 pseudogene on P-450c21 activity and their distribution in patient genomes of congenital steroid 21-hydroxylase deficiency. J. Biochem. 109: 638, 1991.PubMedGoogle Scholar
  34. 34.
    Wu D.A., Chung B. Mutations of P450c21 (steroid 21-hydroxylase) at Cys428, Val281, or Ser268 result in complete, partial, or no loss of enzymatic activity. J. Clin. Invest. 88: 519, 1991.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Mornet E., Crete P., Kuttenn F., et al. Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. Am. J. Hum. Genet. 48: 79, 1991.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Speiser P.W., Dupont J., Zhu D., Serrat J., Buegeleisen M., Tulsie-Luna M.T., Lesser M., New M.I. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Invest. 90: 584, 1992.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Owerbach D., Sherman L., Ballard A.L., Azziz R. Pro 453 to Ser mutation in CYP21 is associated with nonclassical steroid 21-hydroxylase deficiency. Mol. Endocrinol. 6: 1211, 1992.PubMedGoogle Scholar
  38. 38.
    Bobba A., Iolascon A., Giannattasio S., Albrizio M., Sinisi A., Prisco F., Schettini F., Marra E. Characterization of CAH alleles with non-radioactive DNA single strand conformation polymorphism analysis of the CYP21 gene. J. Med. Genet. 34: 223, 1997.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Owerbach D., Ballard A.L., Drazin M.B. Salt-wasting congenital adrenal hyperplasia: Detection and Characterization of mutations in the steroid 21-hydroxylase gene, CYP21, using polymerase chain reaction. J. Clin. Endocrinol. Metab. 74: 553, 1992.PubMedGoogle Scholar
  40. 40.
    Wilson R.C., Cheng K.C., Mercardo A.B., New M.I. Rapid deoxyribbonucleic acid analysis by allele-specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene. J. Clin. Endocrinol. Metab. 80: 1635, 1995.PubMedGoogle Scholar
  41. 41.
    Knochenhauer E.S., Cortet-Rudelli C., Cunningham R.D., Conway-Myers B.A., Dewailly D., Azziz R. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J. Clin. Endocrinol. Metab. 82: 479, 1997.PubMedGoogle Scholar
  42. 42.
    Azziz R., Slayden S.M. Mechanisms of steroid excess in 21-hydroxylase deficient non-classic adrenal hyperplasia. J. Soc. Gynecol. Invest. 3: 297, 1996.CrossRefGoogle Scholar
  43. 43.
    Sydnor K.L., Kelley V.C., Raile R.B., Ely R.S., Sayers G. Blood adrenocorticotrophin in children with congenital adrenal hyperplasia. Proc. Soc. Exp. Biol. Med. 82: 695, 1953.CrossRefGoogle Scholar
  44. 44.
    Cacciari E., Cicognani A., Pirazzoli P., Tassoni P., Zappulla F., Salardi, Bernardi F., Mazzanti L., Vianelli P. GH, ACTH, TSH, LH, and FSH reserve in prepubertal girls with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 43: 1146, 1976.PubMedCrossRefGoogle Scholar
  45. 45.
    Richards G.E., Grumbach M.M., Kaplan S.L., Conte F.A. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 47: 1208, 1978.PubMedCrossRefGoogle Scholar
  46. 46.
    Moreira A.C., Elias L.L.K. Pituitary-adrenal responsestocorticotropin-releasing hormone in different degrees of adrenal 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 74: 198, 1992.PubMedGoogle Scholar
  47. 47.
    Feuillan P., Pang S., Schürmeyer T., Avgerinos P.C., Chrousos G.P. The hypothalamic-pituitary-adrenal axis in partial (late-onset) 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 67: 154, 1988.PubMedCrossRefGoogle Scholar
  48. 48.
    Carmina E., Lobo R. Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency. Fertil. Steril. 54: 79, 1990.PubMedGoogle Scholar
  49. 49.
    Ghizzoni L., Bernasconi S., Virdis R., Vottero A., Ziveri M., Volta C., Iughetti L., Giovannelli G. Dynamics of 24-hour pulsatile cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal patients with nonclassic 21-hydroxylase deficiency and normal prepubertal children. Metabolism 43: 372, 1994.PubMedCrossRefGoogle Scholar
  50. 50.
    Azziz R., Kenney P.H. Magnetic resonance imaging of the adrenal gland in women with late-onset adrenal hyperplasia. Fertil. Steril. 56: 142, 1991.PubMedGoogle Scholar
  51. 51.
    Kater C.E., Biglieri E.G., Wajchenberg B.E. Effects of continued adrenal corticotropin stimulation on the mineralocorticoid hormones in classical and nonclassical symbol virilizing types of 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 60: 1057, 1985.PubMedCrossRefGoogle Scholar
  52. 52.
    Waterman M.R., Mason J.I., Zuber M.X., Lorence M.C., Clark B.J., Trant J.M., Barnes H.J., Simpson E.R., Estabrook R.W. Expression of P-450 enzyme activities in heterologous cells by transfection. Arch. Toxicol. 13: 155, 1989CrossRefGoogle Scholar
  53. 53.
    Lin D., Harikrishna J.A., Moore C.C.D., Jones K.L., Miller W.L. Missense mutation Ser106 Pro causes 17α-hydroxylase deficiency. J. Biol. Chem. 266: 15992.Google Scholar
  54. 54.
    Lobo R.A., Goebelsmann U. Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycistic ovarian disease. Am. J. Obstet. Gynecol. 138: 720, 1980.PubMedGoogle Scholar
  55. 55.
    Chrousos G.P., Loriaux D.L., Mann D.L., Curtler G.B. Late-onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease: An allelic variant of congenital virilizing adrenal hyperplasia with a milder enzymatic defect. Ann. Intern. Med. 96: 143, 1982.PubMedCrossRefGoogle Scholar
  56. 56.
    Carmina E., Malizia G., Pagano M., Janni A. Prevalence of late-onset 11 beta-hydroxylase deficiency in hirsute patients. J. Endocrinol. Invest. 11: 595, 1988.PubMedCrossRefGoogle Scholar
  57. 57.
    Schram P., Zerah M., Mani P., Jewelewics R., Jaffe S., New M.I. Nonclassical 3β-hydroxysteroid dehydrogenase deficiency: A review of our experience with 25 female patients. Fertil. Steril. 58: 129, 1992.PubMedGoogle Scholar
  58. 58.
    Carmina E., Lobo R.A. Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Fertil. Steril. 62: 738, 1994.PubMedGoogle Scholar
  59. 59.
    Azziz R., Markham S., Huth J., Smith B., Zacur H.A. Long-term follow-up of hyperandrogenic women with adrenal 21-hydroxylase deficiency. Am. Fertil. Soc. P–144, 1988 (Abstract).Google Scholar
  60. 60.
    Schiebinger R.J., Albertson B.D., Cassorla F.G., Bowyer D.W., Geelhoed G.W., Cutler G.B., Loriaux D.L The developmental changes in plasma adrenal androgens during infancy and adrenarche are associated with changing activities of adrenal microsomal 17-hydroxylase and 17, 20-desmolase. J. Clin. Invest. 67: 1177, 1981.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Dickerman Z., Grant D.R., Faiman C., Winter J.S.D. Intraadrenal steroid concentrations in man: zonal differences and developmental changes. J. Clin. Endocrinol. Metab. 59: 1031, 1984.PubMedCrossRefGoogle Scholar
  62. 62.
    Mellon S.H., Miller W.L. Extra-adrenal steroid 21-hydroxylase is not mediated by P450c21. J. Clin. Invest. 84: 1497, 1989.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Speiser P.W., Agdere L., Veshiba H., White P.C., New M.I. Aldosterone synthesis in patients with salt-wasting congenital adrenal hyperplasia (21-hydroxylase deficiency) and complete absence of adrenal 21-hydroxylase (P450c21). N. Engl. J. Med. 3221: 145, 1991.CrossRefGoogle Scholar
  64. 64.
    Fiet J., Gueux B., Gourmelen M., Kuttenn F., Vexiau P., Couillin P., Pham-Huu-Trung M.T., Villette J.M., Raux-Demay M.C., Galons H., et al. Comparison of basal and adrenocorticotropin-stimulated plasma 21-desoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia. J. Clin. Endocrinol. Metab. 66: 659, 1988.PubMedCrossRefGoogle Scholar
  65. 65.
    New M.I., Lorenzen F., Lerner A.J., Kohn B., Oberfield S.E., Pollack M.S., Dupont B., Stoner E., Levy D.J., Pang S., Levine L.S. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J. Clin. Endocrinol. Metab. 57: 320, 1983.PubMedCrossRefGoogle Scholar
  66. 66.
    Azziz R., Hincapie L.A., Conway-Myers B.A., Knochenhauer E.S., Fox L., Dewailly D., Cortet-Rudelli C., Boots L.R. Screening for 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH) in hyperandrogenic (HA) women: A prospective study. Endocrine Society, OR03-6 (Abstract).Google Scholar
  67. 67.
    Gutai J.P., Kowarski A.A., Migeon C.J. The detection of the heterozygote carrier for congenital virilizing adrenal hyperplasia. J. Pediatr. 90: 924, 1977.PubMedCrossRefGoogle Scholar
  68. 68.
    Azziz R., Bradley E. Jr., Huth J., Parker C.R. Jr., Zacur H.A. Acute adrenocorticotropin- (1–24) (ACTH) adrenal stimulation in eumenorrheic women: Reproducibility and effect of ACTH dose, subject weight and sampling time. J. Clin. Endocrinol. Metab. 70: 1273, 1990.PubMedCrossRefGoogle Scholar
  69. 69.
    Rosenfield R.L., Lucky A.W. Dexamethasone preparation does not alter corticoid and androgen responses to adrenocorticotropin. J. Clin. Endocrinol. Metab. 60: 585, 1985.PubMedCrossRefGoogle Scholar
  70. 70.
    Knochenhauer E.S., Waggoner W.T., Azziz R., Carmina E., Dewailly D., Fruzzetti F., Ibanez L., Marcondes J.A.M., Mendonca B.B., Rohmer V., Speiser P.W., Zacur H.A. Clinical features and genotype of 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH): A multicenter study. Endocrine Society. P1–358, 1997 (Abstract).Google Scholar
  71. 71.
    Knochenhauer E.S., Decanter C., Cortet-Rudeli C., Weil J., Waggoner W.T., Conway-Myers B.A., Dewailly D., Azziz R. Genotype and phenotype in women with 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). American Society for Reproductive Medicine. S39, O–078, 1997 (Abstract).Google Scholar
  72. 72.
    Azziz R., Owerbach D.M. Molecular abnormalities of the 21-hydroxylase gene in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to acute adrenal stimulation. Am. J. Obstet. Gynecol. 172: 914, 1995.PubMedCrossRefGoogle Scholar
  73. 73.
    Azziz R. Abnormalities of adrenocortical steroidogenesis in the polycystic ovary syndrome. In: Azziz R., Nestler J.E., Dewailly D. (Eds.). Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, 1997, p 403.Google Scholar
  74. 74.
    Azziz R., Rafi A., Smith B., Bradley Jr. E., Zacur H.A. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism. J. Clin. Endocrinol. Metab. 70: 431, 1990.PubMedCrossRefGoogle Scholar
  75. 75.
    Azziz R., Wells G., Boots L.R., Zacur H.A., Acton R.T. Abnormalities of 21-hydroxylase gene ratio and adrenal steroidogenesis in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to acute adrenal stimulation. J. Clin. Endocrinol. Metab. 73: 1327, 1991.PubMedCrossRefGoogle Scholar
  76. 76.
    Spritzer P., Billaud L., Thalabard JC., Birman P., Mowszowicz I., Raux-Demay MC., Clair F., Kuttenn F., Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J. Clin. Endocrinol. Metab. 70: 642, 1990.PubMedCrossRefGoogle Scholar
  77. 77.
    Feldman S., Billaud L., Thalabard J.C., Raux-Demay M.C., Mowszowicz I., Kuttenn F., Mauvais-Jarvis P. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 74: 635, 1992.PubMedGoogle Scholar
  78. 78.
    Azziz R., Carmina E., Dewailly D., Fruzzetti F., Marcondes J.A.M., Mendonca B.B., Speiser P.W., Zacur H.A. The risk of delivering a child with classic 21-hydroxylase (21-OH) deficient adrenal hyperplasia (CAH) among women with non-classic adrenal hyperplasia (NCAH): a multicenter study. Endocrine Society. P2–656, 1996 (Abstract).Google Scholar
  79. 79.
    Pang S., Clark A.T., Freeman L.C., Dolan L.M., Immken L., Mueller O.T., Stiff D., Shulman D.I. Maternal side-effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 75: 249, 1992.PubMedGoogle Scholar
  80. 80.
    Temeck J.W., Pang S., Nelson C., New M.I. Genetic defects of steroidogenesis in premature pubarche. J. Clin. Endocrinol. Metab. 64: 609, 1987.PubMedCrossRefGoogle Scholar
  81. 81.
    Hawkins L.A., Chasalow F.I., Blethen S.L. The role of adrenocorticotropin testing in evaluating girls with premature adrenarche and hirsutism/oligomenorrhea. J. Clin. Endocrinol. Metab. 74: 248, 1992.PubMedGoogle Scholar
  82. 82.
    Moran C., Tena G., Herrera J., Bermúdez J.A., Zárate A. Heterogeneity of late-onset adrenal 3β-ol-hydroxysteroid dehydrogenase deficiency in patients with hirsutism and polycystic ovaries. Arch. Med. Res. 25: 315, 1994.PubMedGoogle Scholar
  83. 83.
    Mathieson J., Couzinet B., Wekstein-Noel S., Nahoul K., Turpin G., Schiason G. The incidence of late-onset congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency among hirsute women. Clin. Endocrinol. 36: 383, 1992.CrossRefGoogle Scholar
  84. 84.
    Labrie F., Simard J., Luu-The V., Belanger A., Peletier G. Structure function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/Δ5-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. J. Steroid Biochem. Mol. Biol. 43: 805, 1992.PubMedCrossRefGoogle Scholar
  85. 85.
    Zerah M., Rheaume E., Mani P., Schram P., Simard J., Labrie F., New M.I. No evidence of mutations in the genes for type I and type II 3β-hydroxysteroid dehydrogenase (3β-HSD) in nonclassical 3β-HSD deficiency. J. Clin. Endocrinol. Metab. 79: 1811, 1994.PubMedGoogle Scholar
  86. 86.
    Chang Y.T., Zhang L., Alkaddour H.S., Mason J.I., Lin K., Yang X., Garibaldi L.R., Bourdony C.J., Dolan L.M., Donaldson D.L. Absence of molecular defect in the type II 3β-hydroxysteroid dehydrogenase (3β-HSD) gene in premature pubarche children and hirsute female patients with moderately decreased adrenal 3β-HSD activity. Pediatr. Res. 37: 820, 1995PubMedCrossRefGoogle Scholar
  87. 87.
    Sakkal-Alkaddour H., Zhang L., Yang X., Chang Y.T., Kappy M., Slover R.S., Jorgensen V., Pang S. Studies of 3β-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased ACTH stimulation A5 steroid levels. J. Clin. Endocrinol. Metab. 81: 3961, 1996.PubMedGoogle Scholar
  88. 88.
    Pang S. The molecular and clinical spectrum of 3β-hydroxysteroid dehydrogenase deficiency syndrome. Trends Endocrinol. Metab. 9: 82, 1998PubMedCrossRefGoogle Scholar
  89. 89.
    Bongiovanni A.M., Kellenbenz G. The adrenogenital syndrome with deficiency of 3β-hydroxysteroid dehydrogenase. J. Clin. Invest. 41: 2086, 1962.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Zachmann M., Tassinari D., Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. A study of 25 patients. J. Clin. Endocrinol. Metab. 56: 222, 1983.PubMedCrossRefGoogle Scholar
  91. 91.
    Cathelineau G., Brerault J.L., Fiet J., Julien R., Dreux C., Canivet J. Adrenocortical 11 beta-hydroxylation defect in adult women with postmenarchial onset of symptoms. J. Clin. Endocrinol. Metab. 51: 287, 1980.PubMedCrossRefGoogle Scholar
  92. 92.
    Azziz R., Bradley Jr. E.L., Potter H.D., Boots L.R. 3β-Hydroxysteroid dehydrogenase deficiency in hyperandrogenism. Am. J. Obstet Gynecol. 168: 889, 1993.PubMedCrossRefGoogle Scholar
  93. 93.
    White P.C., Johrer K., Kofier R. Steroid 11β-hydroxylase deficiency. In: Azziz R., Nestler J.E., Dewailly D. (Eds.). Androgen excess disorders in women. Lippincott-Raven Publishers, Philadelphia, 1997, p. 193.Google Scholar
  94. 94.
    Joehrer K., Geley S., Strasser-Wozak E.M.C., Azziz R., Wollmann H.A., Schmitt K., Kofier R., White P. CYP11B1 mutations causing nonclassic adrenal hyperplasia due to 11β-hydroxylase deficiency. Hum. Mol. Genet. 6: 1829, 1997PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1998

Authors and Affiliations

  • C. Morán
    • 1
    • 3
  • E. S. Knochenhauer
    • 1
  • Ricardo Azziz
    • 1
    • 2
  1. 1.Division of Reproductive Biology and Endocrinology, Department of Obstetrics and GynecologyThe University of Alabama at BirminghamBirminghamUSA
  2. 2.Departments of MedicineThe University of Alabama at BirminghamBirminghamUSA
  3. 3.Research Unit of Reproductive MedicineInstituto Mexicano del Seguro SocialMexico CityMexico

Personalised recommendations